Mzia Kutateladze
Laboratory of Molecular Biology
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Mzia Kutateladze.
Microbial Biotechnology | 2011
Leila Kvachadze; Nana Balarjishvili; Tamila Meskhi; Ekaterine Tevdoradze; Natia Skhirtladze; Tamila Pataridze; Revaz Adamia; Temur Topuria; Elizabeth Kutter; Christine Rohde; Mzia Kutateladze
In recent decades the increase in antibiotic‐resistant bacterial strains has become a serious threat to the treatment of infectious diseases. Drug resistance of Staphylococcus aureus has become a major problem in hospitals of many countries, including developed ones. Today the interest in alternative remedies to antibiotics, including bacteriophage treatment, is gaining new ground. Here, we describe the staphylococcal bacteriophage Sb‐1 – a key component of therapeutic phage preparation that was successfully used against staphylococcal infections during many years in the Former Soviet Union. This phage still reveals a high spectrum of lytic activity in vitro against freshly isolated, genetically different clinical samples (including methicillin‐resistant S. aureus) obtained from the local hospitals, as well as the clinics from different geographical areas. The sequence analyses of phage genome showed absence of bacterial virulence genes. A case report describes a promising clinical response after phage application in patient with cystic fibrosis and indicates the efficacy of usage of Sb‐1 phage against various staphylococcal infections.
Biotechnology Journal | 2016
Zemphira Alavidze; Rustam I. Aminov; Alexander Betts; Marjorie Bardiau; Laurent Bretaudeau; Jonathan Caplin; Nino Chanishvili; Aidan Coffey; Ian Cooper; Daniel De Vos; Jir Doskar; Ville-Petri Friman; Naomi Hoyle; Nino Karanadze; D I Kurtboke; Mzia Kutateladze; Shawna McCallin; Maya Merabishvili; George Mgaloblishvili; Lia Nadareishvili; Nikoloz Nikolaishvili; Dea Nizharadze; Pantucek Roman; Jean-Paul Pirnay; Grégory Resch; Christine Rohde; Wilbert Sybesma; Teona Shulaia; Marina Tediashvili; Aleksandre Ujmajuridze
This multidisciplinary expert panel opinion on bacteriophage therapy has been written in the context of a society that is confronted with an ever-increasing number of antibiotic resistant bacteria. To avoid the return to a pre-antibiotic era, alternative treatments are urgently needed. The authors aim to contribute to the opinion formation of relevant stakeholders on how to potentially develop an infrastructure and legislation that paves the way for the acceptance and re-implementation of bacteriophage therapy.
Frontiers in Microbiology | 2016
Wilbert Sybesma; Reinhard Zbinden; Nino Chanishvili; Mzia Kutateladze; Archil Chkhotua; Aleksandre Ujmajuridze; Ulrich Mehnert; Thomas M. Kessler
Background: Urinary tract infections (UTIs) are among the most prevalent microbial diseases and their financial burden on society is substantial. The continuing increase of antibiotic resistance worldwide is alarming so that well-tolerated, highly effective therapeutic alternatives are urgently needed. Objective: To investigate the effect of bacteriophages on Escherichia coli and Klebsiella pneumoniae strains isolated from the urine of patients suffering from UTIs. Material and methods: Forty-one E. coli and 9 K. pneumoniae strains, isolated from the urine of patients suffering from UTIs, were tested in vitro for their susceptibility toward bacteriophages. The bacteriophages originated from either commercially available bacteriophage cocktails registered in Georgia or from the bacteriophage collection of the George Eliava Institute of Bacteriophage, Microbiology and Virology. In vitro screening of bacterial strains was performed by use of the spot-test method. The experiments were implemented three times by different groups of scientists. Results: The lytic activity of the commercial bacteriophage cocktails on the 41 E. coli strains varied between 66% (Pyo bacteriophage) and 93% (Enko bacteriophage). After bacteriophage adaptation of the Pyo bacteriophage cocktail, its lytic activity was increased from 66 to 93% and only one E. coli strain remained resistant. One bacteriophage of the Eliava collection could lyse all 9 K. pneumoniae strains. Conclusions: Based on the high lytic activity and the potential of resistance optimization by direct adaption of bacteriophages as reported in this study, and in view of the continuing increase of antibiotic resistance worldwide, bacteriophage therapy is a promising treatment option for UTIs highly warranting randomized controlled trials.
Frontiers of Medicine in China | 2017
Pikria Zhvania; Naomi Hoyle; Lia Nadareishvili; Dea Nizharadze; Mzia Kutateladze
Netherton syndrome (NS) is a rare autosomal recessive disorder, characterized by a classical triad of clinical features, including congenital ichthyosiform erythroderma, trichorrhexis invaginata, and atopic diathesis coupled with frequent bacterial infections (1). The genetic basis for the disease has been recently identified with mutations in gene SPINK5, which is involved in the regulation of formation of skin barriers. We report on a 16-year-old male with all the typical manifestations of NS, including atopic diathesis and ongoing serious staphylococcal infections and allergy to multiple antibiotics whose family sought help at the Eliava Phage Therapy Center when all other treatment options were failing. Treatment with several antistaphylococcal bacteriophage preparations led to significant improvement within 7 days and very substantial changes in his symptoms and quality of life after treatment for 6 months, including return visits to the Eliava Phage Therapy Center after 3 and 6 months of ongoing use of phage at home.
Virology Journal | 2015
Ekaterine Tevdoradze; Jason Farlow; Adam Kotorashvili; Natia Skhirtladze; Irina Antadze; Sophio Gunia; Nana Balarjishvili; Leila Kvachadze; Mzia Kutateladze
BackgroundRecently the genome sequences of two brucellaphages, isolated in Georgia (Tb) and Mexico (Pr) were reported revealing pronounced sequence homogeneity and the presence of two major indels discriminating the two phages. Subsequent genome sequencing of six diagnostic brucellaphages: Tbilisi (Tb), Firenze (Fz), Weybridge (Wb), S708, Berkeley (Bk) and R/C phages identified three major genetic groups. However, the propensity for fine-scale genetic variability of diverse brucellaphages grown on multiple hosts within a single Brucella species remains unknown.MethodsWe sequenced the complete genomes of ten brucellaphages following initial propagation on B. abortus strain 141 and after subsequent propagation on B. abortus strain S19. All brucellaphages were isolated and propagated at the Eliava Institute including the original Tb phage. Genomic libraries were quantified using the Qbit and sheared on the Covaris M220. QC for fragmentation was performed on the BioAnalyzer 2100. DNA libraries were prepared using an Illumina Paired-End protocol and sequenced on the Illumina MiSeq. Sequence analysis was performed using Geneious and MEGA software.ResultsComparative whole genome sequence analysis revealed genetic homogeneity consistent with previously published data as well as multiple nucleotide variations. Genomic changes as a result of passages were observed in similar genes and predominantly occurred at identical sites in separate phages. Multiple instances of within-sample genetic heterogeneity were observed often at shared genomics positions across phages. Positive selection was detected in the tail collar protein gene. We also identified a Staphylothermus marinus F1-like CRISPR spacer and sequences orthologous to both prophage antirepressors of Brucella spp. and intergenic sequences encoded by Ochrobactrum anthropi.ConclusionWe surveyed whole genome level diversity in phage lytic for B. abortus as they are propagated on alternate vaccine strains within the species. Our data extend previous results indicating select variable hotspots and broad genomic homogeneity as well as multiple common polymorphisms and within-sample variation. These data also provide additional genomes for future reference in comparative studies involving the molecular evolution and host specificity of brucellaphages.
Current Microbiology | 2014
Ekaterine Tevdoradze; Leila Kvachadze; Mzia Kutateladze; Charles R. Stewart
Bacteriophage genes offer a potential resource for development of new antibiotics. Here, we identify at least six genes of Staphylococcus aureus phage Sb-1 that have bactericidal activity when expressed in Escherichia coli. Since the natural host is gram-positive, and E. coli is gram-negative, it is likely that a variety of quite different bacterial pathogens would be susceptible to each of these bactericidal activities, which therefore might serve as the basis for development of new wide-spectrum antibiotics. We show that two of these gene products target E. coli protein synthesis.
Applied Biochemistry and Microbiology | 2015
N. Sh. Balarjishvili; Leila Kvachadze; Mzia Kutateladze; T. Sh. Meskhi; T. K. Pataridze; T. A. Berishvili; E. Sh. Tevdoradze
The sensitivity of 512 newly isolated Pseudomonas aeruginosa clinical strains to six classes of antimicrobial preparations has been studied. Antibiotic-resistant strains were selected and genotyped. Three new virulent bacteriophages of the families Myoviridae and Podoviridae were isolated against these strains. The parameters of the intracellular phage development cycle were established, and the influence of inactivating factors (temperature, pH, and UV exposure) on phage viability was studied. The molecular weight of the phage genome was determined. Phage DNA restriction analysis and structural protein composition analysis by SDS polyacrylamide gel electrophoresis were carried out. The plating efficacy of phages on 28 genetically distant antibiotic-resistant P. aeruginosa strains was studied. It was established that 26 of them were lysed by phages with a high efficacy. The range of antibacterial action of the studied phages and their mixtures on 427 multidrug-resistant clinical isolates was assessed. It is shown that including these phages in one multicomponent preparation enhanced their lytic activity.
Journal of Antimicrobial Chemotherapy | 2014
Deirdre Fitzgerald-Hughes; Darajen Bolkvadze; Nana Balarjishvili; Lika Leshkasheli; Maia Ryan; Liam Burke; Niall T. Stevens; Hilary Humphreys; Mzia Kutateladze
Archive | 2018
Randolph Fish; Elizabeth Kutter; Gordon Wheat; Bob G. Blasdel; Mzia Kutateladze; Sarah Kuhl
Archive | 2016
Wilbert Sybesma; Jean-Paul Pirnay; Zemphira Alavidze; Rustam I. Aminov; Alexander Betts; Marjorie Bardiau; Laurent Bretaudeau; Jonathan Caplin; Nino Chanishvili; Aidan Coffey; Ian Cooper; Daniel De Vos; Jiří Doškař; Ville-Petri Friman; Naomi Hoyle; Nino Karanadze; Ipek Kurtboke; Mzia Kutateladze; Shawna McCallin; Maya Merabishvili; George Mgaloblishvili; Lia Nadareishvili; Nikoloz Nikolaishvili; Dea Nizharadze; Roman Pantůček; Grégory Resch; Christine Rohde; Teona Shulaia; Marina Tediashvili; Aleksandre Ujmajuridze